157 related articles for article (PubMed ID: 33404182)
1. Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia.
Li ZB; Li L; Niu XX; Chen SH; Fu YM; Wang CY; Liu Y; Shao Q; Chen G; Ji D
Liver Int; 2021 Jun; 41(6):1254-1264. PubMed ID: 33404182
[TBL] [Abstract][Full Text] [Related]
2. Long-term health and economic benefits of switching to tenofovir alafenamide versus continuing on entecavir in chronic hepatitis B patients with low-level viremia in Saudi Arabia.
Sanai FM; Aljawad M; Alghamdi AS; Yehoshua A; Khathlan A; Alghamdi M; Kozma S; Smith N; El-Moustaid F; Jeyakumar S; Kachru N
Saudi J Gastroenterol; 2024 Jan; 30(1):23-29. PubMed ID: 37417192
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy.
Fang HW; Tseng PL; Hu TH; Wang JH; Hung CH; Lu SN; Chen CH
Virol J; 2024 Apr; 21(1):79. PubMed ID: 38570803
[TBL] [Abstract][Full Text] [Related]
4. Comparison of tenofovir alafenamide and entecavir for hepatitis B virus
Peng W; Gu H; Jiang C; Liu J; Zhang J; Fu L
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Feb; 47(2):194-201. PubMed ID: 35545409
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of tenofovir alafenamide in patients with chronic hepatitis B exhibiting suboptimal response to entecavir.
Yuan GC; Chen AZ; Wang WX; Yi XL; Tu L; Peng F; Qiu ZH
World J Clin Cases; 2023 Dec; 11(34):8139-8146. PubMed ID: 38130795
[TBL] [Abstract][Full Text] [Related]
6. Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study.
Ogawa E; Nakamuta M; Koyanagi T; Ooho A; Furusyo N; Kajiwara E; Dohmen K; Kawano A; Satoh T; Takahashi K; Azuma K; Yamashita N; Yamashita N; Sugimoto R; Amagase H; Kuniyoshi M; Ichiki Y; Morita C; Kato M; Shimoda S; Nomura H; Hayashi J;
Aliment Pharmacol Ther; 2022 Aug; 56(4):713-722. PubMed ID: 35735794
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece.
Sinakos E; Kachru N; Tsoulas C; Jeyakumar S; Smith NJ; Yehoshua A; Cholongitas E
J Comp Eff Res; 2024 Apr; 13(4):e230090. PubMed ID: 38317634
[No Abstract] [Full Text] [Related]
8. Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data.
Lim YS; Seto WK; Kurosaki M; Fung S; Kao JH; Hou J; Gordon SC; Flaherty JF; Yee LJ; Zhao Y; Agarwal K; Lampertico P
Aliment Pharmacol Ther; 2022 Apr; 55(8):921-943. PubMed ID: 35178711
[TBL] [Abstract][Full Text] [Related]
9. Risk factors of low-level viremia in chronic hepatitis B patients receiving Entecavir monotherapy: a retrospective cohort study.
Chen H; Fu JJ; Li L; Wang X; Pan XC
J Gastroenterol Hepatol; 2024 Jan; 39(1):180-184. PubMed ID: 37718592
[TBL] [Abstract][Full Text] [Related]
10. Switching from combination therapy with entecavir hydrate plus tenofovir alafenamide fumarate to tenofovir alafenamide fumarate monotherapy in patients with chronic hepatitis B based on nucleotide sequences of hepatitis B virus pregenome RNA.
Yamada S; Uchida Y; Kouyama JI; Naiki K; Tsuji S; Uemura H; Sugawara K; Nakayama N; Imai Y; Tomiya T; Mizuno S; Mochida S
Hepatol Res; 2024 Mar; ():. PubMed ID: 38517681
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir amibufenamide
Peng WT; Jiang C; Yang FL; Zhou NQ; Chen KY; Liu JQ; Peng SF; Fu L
World J Gastroenterol; 2023 Nov; 29(44):5907-5918. PubMed ID: 38111506
[TBL] [Abstract][Full Text] [Related]
12. Risk of hepatocellular carcinoma after curative treatment when switching from tenofovir disoproxil fumarate or entecavir to tenofovir alafenamide: A real-world multicenter cohort study.
Shin H; Kim SU; Song BG; Park Y; Ko Y; Park J; Hur MH; Lee YB; Cho EJ; Lee JH; Yu SJ; Yoon JH; Sinn DH; Kim YJ
Hepatol Res; 2024 Feb; ():. PubMed ID: 38300711
[TBL] [Abstract][Full Text] [Related]
13. A Real-World Study on Safety and Efficacy of TAF Treatment in HBV Patients with High Risk of Osteoporosis or Osteopenia in China.
Li C; Li H; Gong M; Liu Y; Zhang R; Geng J; Wang H; Yu Z; Wang Z; Liu X; Wei J
Altern Ther Health Med; 2024 Jan; ():. PubMed ID: 38294749
[TBL] [Abstract][Full Text] [Related]
14. Noninferiority Outcomes of Besifovir Compared to Tenofovir Alafenamide in Treatment-Naïve Patients with Chronic Hepatitis B.
Kim TH; Kim JH; Yim HJ; Seo YS; Yim SY; Lee YS; Jung YK; Yeon JE; Um SH; Byun KS
Gut Liver; 2024 Mar; 18(2):305-315. PubMed ID: 38213189
[TBL] [Abstract][Full Text] [Related]
15. Cost-Utility Analysis of Tenofovir Alafenamide and Entecavir in Chronic Hepatitis B Patients: A Markov Decision Model.
Lai CH; Shi HY; Tsai CE; Yang YC; Chiu SF
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398204
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal changes in renal function in patients with chronic hepatitis B on antiviral treatment.
Hong H; Cho M; Lim C; Choi WM; Lee D; Shim JH; Kim KM; Lim YS; Lee HC; Choi J
Aliment Pharmacol Ther; 2024 Feb; 59(4):515-525. PubMed ID: 38009290
[TBL] [Abstract][Full Text] [Related]
17. Effects of entecavir and tenofovir alafenamide fumarate treatment on renal function in Japanese elderly patients with chronic hepatitis B.
Tanaka M; Akahane T; Kawaratani H; Yorioka N; Koizumi A; Asada S; Matsuda T; Iwai S; Tsuji Y; Fujinaga Y; Nishimura N; Kitagawa K; Kaji K; Namisaki T; Yoshiji H
Hepatol Res; 2024 Mar; 54(3):252-260. PubMed ID: 37897705
[TBL] [Abstract][Full Text] [Related]
18. Sequential therapy from entecavir to tenofovir alafenamide
Itokawa N; Atsukawa M; Tsubota A; Takaguchi K; Nakamuta M; Hiraoka A; Kato K; Abe H; Mikami S; Shimada N; Chuma M; Akito N; Uojima H; Ogawa C; Asano T; Tani J; Morishita A; Senoh T; Yamashita N; Oikawa T; Matsumoto Y; Koeda M; Yoshida Y; Tanabe T; Okubo T; Arai T; Hayama K; Iwashita AN; Kondo C; Tada T; Toyoda H; Kumada T; Iwakiri K
JGH Open; 2021 Jan; 5(1):34-40. PubMed ID: 33490611
[TBL] [Abstract][Full Text] [Related]
19. The 48-week safety and therapeutic effects of tenofovir alafenamide in hbv-related acute-on-chronic liver failure: A prospective cohort study.
Zhang Y; Xu W; Zhu X; Li X; Li J; Shu X; Lai J; Xie J; Xie C; Peng L
J Viral Hepat; 2021 Apr; 28(4):592-600. PubMed ID: 33423348
[TBL] [Abstract][Full Text] [Related]
20. Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir.
Suzuki F; Sezaki H; Hosaka T; Suzuki Y; Fujiyama S; Kawamura Y; Akuta N; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
Hepatol Res; 2021 Apr; 51(4):503-508. PubMed ID: 33462964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
